Reading this on a mobile device? Try our optimized mobile version here:

December 28, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Why Kalydeco is the FDA's biggest approval of 2012
    Of the 40 new drug approvals by the FDA this year, one stands out above the rest, Matthew Herper writes. The Cystic Fibrosis Foundation played a pivotal role in the development of Vertex's cystic fibrosis treatment Kalydeco, which directly acts on a gene that can cause cystic fibrosis, and groups such as the Michael J. Fox Foundation, the Multiple Myeloma Research Foundation and Myelin Repair are playing similar roles in drug development. Forbes (12/27) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Celator begins Phase III study of injectable AML drug
    Celator Pharmaceuticals has started enrolling patients in a late-stage trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with high-risk acute myeloid leukemia. The multicenter trial will be carried out in the U.S. and Canada. "The initiation of this study is an important milestone for CPX-351 and for Celator. We hope the data it provides will allow us to seek regulatory approval for CPX-351," Celator CEO Scott Jackson said. Pharmaceutical Business Review Online (12/27) LinkedInFacebookTwitterEmail this Story
  • Alnylam CEO predicts more NME approvals in 2013
    Drugmakers have improved at developing innovative medicines, and the FDA has struck a better balance in assessing risks and benefits, writes Alnylam Pharmaceuticals CEO John Maraganore. The result will be increasing approvals of new molecular entities, he predicts. Xconomy/Boston (12/26) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.
  Food & Agriculture 
  • Fast food -- not biotech salmon -- is the real threat to health
    AquaBounty Technologies' transgenic salmon is safe while the fast food Americans consume daily is not, bioethicist Art Caplan writes. Consumers shouldn't worry about the FDA's finding that there is no valid scientific reason to ban the sale of the biotech fish, according to Caplan, while consumer groups should focus their criticism on real threats. "Those who care about public health should not target bigger fish but the drive-thru," he writes. NBC News/Vitals blog (12/27) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Researchers seek bioenergy crops for marginal lands in S.C.
    Researchers at the University of South Carolina and Clemson University are working together to test fast-growing, high-volume biomass crops such as energy cane for biofuel production. The project's goal is to develop bioenergy crops that can be grown profitably on marginal lands in South Carolina, said Steve Kresovich, a biologist at USC. (12/26) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

If all misfortunes were laid in one common heap whence everyone must take an equal portion, most people would be contented to take their own and depart."
Greek philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information